Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:CMMB NASDAQ:PHXM NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.29+29.0%$0.77$0.46▼$1.32$14.24M0.316,115 shs54,605 shsCMMBChemomab Therapeutics$1.70+4.9%$1.70$1.35▼$4.92$12.24M0.6259,402 shs62,969 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AVIVSVivoSim Labs$1.06-0.9%$1.28$0.95▼$5.30$2.77M1.38856,387 shs115,654 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+11.10%+9.89%+33.33%+5.29%-10.71%CMMBChemomab Therapeutics0.00%+8.00%-19.00%+1.89%-65.09%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%VIVSVivoSim Labs+0.94%-5.31%-18.32%-33.95%-27.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.29+29.0%$0.77$0.46▼$1.32$14.24M0.316,115 shs54,605 shsCMMBChemomab Therapeutics$1.70+4.9%$1.70$1.35▼$4.92$12.24M0.6259,402 shs62,969 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AVIVSVivoSim Labs$1.06-0.9%$1.28$0.95▼$5.30$2.77M1.38856,387 shs115,654 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+11.10%+9.89%+33.33%+5.29%-10.71%CMMBChemomab Therapeutics0.00%+8.00%-19.00%+1.89%-65.09%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%VIVSVivoSim Labs+0.94%-5.31%-18.32%-33.95%-27.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ACMMBChemomab Therapeutics 2.00Hold$25.001,370.59% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/AVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, CMMB, PHXM, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026CMMBChemomab Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$2.00 per shareN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/AVIVSVivoSim Labs$140K19.76N/AN/A$5.54 per share0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$1.64N/AN/AN/AN/AN/A-519.50%8/17/2026 (Estimated)CMMBChemomab Therapeutics-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%8/13/2026 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/AN/AN/AN/AN/AN/AN/AN/AVIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest VIVS, CMMB, PHXM, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CMMBChemomab Therapeutics-$0.04-$0.22-$0.18$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21CMMBChemomab TherapeuticsN/A10.3110.31PHXMPHAXIAM Therapeutics0.231.78N/AVIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CMMBChemomab Therapeutics46.05%PHXMPHAXIAM Therapeutics0.40%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%CMMBChemomab Therapeutics11.91%PHXMPHAXIAM Therapeutics1.94%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableCMMBChemomab Therapeutics207.20 million6.34 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataVIVSVivoSim Labs202.61 million2.54 millionN/AVIVS, CMMB, PHXM, and BCLI HeadlinesRecent News About These CompaniesVivoSim Labs Delays Annual SEC FilingJune 29 at 6:30 PM | tipranks.comVivoSim Skids on DataJune 29 at 10:52 AM | baystreet.caVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology MeetingJune 29 at 8:05 AM | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) SEC FilingsJune 29 at 5:52 AM | nasdaq.comVivoSim Labs, Inc. Common StockJune 26, 2026 | fxempire.comFVivoSim Labs Inc VIVSMay 17, 2026 | morningstar.comMVivoSim Labs IncMay 14, 2026 | cnn.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | financialpost.comFVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | financialpost.comFVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | globenewswire.comVivoSim Labs Stock Price HistoryMarch 4, 2026 | investing.comVivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 4, 2026 | finanznachrichten.deVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | financialpost.comFVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | globenewswire.comVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIVS, CMMB, PHXM, and BCLI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.29 +0.29 (+29.00%) As of 03:59 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Chemomab Therapeutics NASDAQ:CMMB$1.70 +0.08 (+4.94%) Closing price 03:59 PM EasternExtended Trading$1.72 +0.02 (+0.88%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 06/30/2026PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.VivoSim Labs NASDAQ:VIVS$1.06 -0.01 (-0.93%) Closing price 04:00 PM EasternExtended Trading$1.05 -0.01 (-1.32%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
